Funding Opportunity ID: |
321295 |
Opportunity Number: |
RFA-NS-20-008 |
Opportunity Title: |
HEAL Initiative: Development of Therapies and Technologies Directed at Enhanced Pain Management (R41/R42 Clinical Trial Required) |
Opportunity Category: |
Discretionary |
Opportunity Category Explanation: |
|
Funding Instrument Type: |
Grant |
Category of Funding Activity: |
Education Food and Nutrition Health Income Security and Social Services |
Category Explanation: |
|
CFDA Number(s): |
93.213 93.233 93.273 93.286 93.393 93.394 93.395 93.399 93.837 93.838 93.839 93.840 93.847 93.853 93.859 93.865 93.866 93.867 |
Eligible Applicants: |
Small businesses |
Additional Information on Eligibility: |
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. see the funding announcement for eligibility details |
Agency Code: |
HHS-NIH11 |
Agency Name: |
Department of Health and Human Services National Institutes of Health |
Posted Date: |
Oct 04, 2019 |
Close Date: |
Sep 08, 2022 |
Last Updated Date: |
Oct 04, 2019 |
Award Ceiling: |
$0 |
Award Floor: |
$0 |
Estimated Total Program Funding: |
|
Expected Number of Awards: |
|
Description: |
The purpose of this Funding Opportunity Announcement (FOA) aims to speed scientific solutions to stem the national opioid public health crisis by supporting the development of therapies and technologies directed at enhanced pain management through the Small Business Technology Transfer (STTR) program. This FOA is focused on applications directed at improving pain treatment, including the development of new non-addictive medications and devices and objective pain measurement. In addition, NIH is interested in new screening tools and models focused specifically on pain and development of pain therapies. |
Version: |
1 |